FDFatma Demirbaş

Fatma Demirbaş

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fatma Demirbaş has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of liver function tests in children with food allergies

    by Ilknur Kaba, Fatma Demirbaş Ar, Perihan Kirali, Atakan Comba

    The aim of this study was to investigate liver function tests and their association with clinical characteristics in children diagnosed with non-IgE-mediated food allergy. A total of 132 children with non-IgE-mediated food allergies and 127 age- and sex-matched healthy controls were retrospectively analyzed. Patient demographics, clinical features and response to treatment were analyzed. Serum aspartate aminotransferase and alanine aminotransferase (ALT) levels were measured in both groups. The mean age of the patients was 6.0 ± 3.2 months, and symptoms appeared on average at 4.0 ± 3.4 months. At the time of symptom onset, 69 children (52.2%) were exclusively breastfed. The most common symptoms were mucous (56.8%) and bloody stools (47%). Food protein-induced proctocolitis was diagnosed in 104 patients (78.8%), food protein-induced enterocolitis syndrome in 18 (13.6%) and food protein-induced enteropathy in 10 (7.6%). Cow’s milk (86.3%) and egg (34%) were the most common allergens. Mean ALT levels were significantly higher in patients (35.1 ± 30.6 U/L) than in controls (23.2 ± 8.6 U/L; P = .009), and ALT elevation was observed in 10.6% of patients versus 3.1% of controls ( P = .026). Transaminase levels normalized on average within 3.9 ± 1.4 months after diet elimination. No significant differences were observed between children with elevated and normal ALT levels with respect to age, gender, diet, diagnosis or atopy. A mild elevation of liver enzyme may occur in children with non-IgE-mediated food allergies and usually disappears with elimination of the food. Clinicians should consider this association at diagnosis and delay invasive interventions until dietary intervention has been attempted.

  • Open Access

    The role of inborn errors of metabolism in the etiology of neonatal cholestasis: A single center experience

    by Ayse Ergül Bozacı, Fatma Demirbaş Ar, Aysel Tekmenuray Ünal, İbrahim Taş, Hüseyin Bilgin

    Objective: The evaluation of patients with neonatal cholestasis is difficult due to the variety of cholestatic syndromes and non-specific clinical findings. It is important to recognize treatable diseases promptly. The aim of this study is to draw attention to suspicious markers in order to diagnose treatable metabolic diseases. Method: The presented retrospective study included patients with cholestasis in the first three months of life. The study was conducted between 2018 and 2021 at Diyarbakır Children’s Hospital, Türkiye. Results: 253 patients presenting with neonatal cholestasis were retrospectively evaluated. 174 patients (68.77%) were examined for intrahepatic cholestasis. 16.6% of the patients were diagnosed with an infection, 13.43% with TPN-related cholestasis, 8.3% with IEM, 7.11% with cystic fibrosis, 4.74% with endocrinopathy, 4.34% patients with Alpha-1 antitrypsin deficiency, 2.76% with idiopathic neonatal hepatitis, 1.97% with genetic syndrome, 1.58% with PFIC, and 0.79% patients with Alagille syndrome. IEM-related patients (21) were diagnosed with tyrosinemia type 1, galactosemia, Niemann-Pick type A, glycogen storage disease type 3, peroxisomal disorders, fatty acid oxidation defects, mitochondrial DNA depletion syndrome, citrine deficiency, Niemann-Pick Type C and bile acid synthesis defect. Plasma tyrosine and methionine levels were high in patients with not only tyrosinemia type 1, but also galactosemia and citrine deficiency. Therapeutic plasma exchange was performed in two patients with fatty acid oxidation disorders. Conclusion: Neonatal cholestasis poses a diagnostic challenge for clinicians. Delayed referral to a specialist for treatable metabolic diseases may increase mortality and morbidity. IEMs are observed more frequently in the etiologies of neonatal cholestasis in Türkiye due to high parental consanguinity and inadequate newborn screening programs. Treatable disorders should be considered early, as therapeutic interventiosn can be lifesaving. It also helps in genetic counseling, prenatal diagnosis for future pregnancies.


  • Open Access

    Fecal calprotectin levels used as a noninvasive method for screening for chronic gastritis in pediatric patients. A descriptive study

    by Fatma Demirbaş, Gönül Çaltepe, Hasan Abbasguliyev, Ayhan Gazi Kalaycı

    BACKGROUND: Gastritis consists of inflammation of the gastric mucosa and is one of the main causes of dyspeptic symptoms in children. OBJECTIVE: To investigate the presence of inflammation by evaluating fecal calprotectin (FC) in children diagnosed with chronic gastritis. DESIGN AND SETTING: Descriptive study in Pediatric Gastroenterology Department of Ondokuz Mayis University Hospital in Turkey. METHODS: Between January 2016 and July 2018, FC levels were compared retrospectively in children with chronic gastritis (histopathology-based diagnosis), patients with inflammatory bowel disease (IBD) and healthy children. RESULTS: A total of 67 chronic gastritis patients (61.2% girls) with a mean age of 13.09 +/- 3.5 years were evaluated. The mean FC levels were 153.4 mu g/g in the chronic gastritis group, 589.7 mu g/g in the IBD group and 43.8 mu g/g in the healthy group. These levels were higher in chronic gastritis patients than in healthy individuals (P = 0.001) and higher in IBD patients than in the other two groups (P < 0.001). The FC level in the patients with chronic active gastritis (156.3 mu g/g) was higher than in those with chronic inactive gastritis (150.95 mu g/g) (P = 0.011). Among the patients with chronic active gastritis, the FC level was significantly higher in Helicobacter pylori-positive individuals than in negative individuals (P = 0.031). CONCLUSION: We confirmed the association between increased FC and chronic gastritis. Elevated FC levels may be seen in patients with chronic active gastritis. In order to be able to use FC as a screening tool for chronic gastritis, further studies in a larger study group are needed.


  • Çölyak Hastalığının Genetik Allel Dağılımının Değerlendirilmesi ve Türkiye Literatür Taraması

    by Fatma Demi̇rbaş, Aslıhan SANRI, Gönül Di̇nler Çaltepe, Atakan Comba, Ayhan Gazi Kalayci

    Amaç: Çölyak hastalığı (ÇH), genetik yatkınlığı olan bireylerde, glutene kalıcı duyarlılık sonucu gelişen, otoimmün, sistemik hastalıktır. Bu çalışmanın amacı, ÇH’nin klinik, laboratuar özellikleri ve HLA doku tiplerinin geriye dönük değerlendirilmesidir.Ayrıca lieratür taramasıyla HLA doku tipleri açısından Türkiye’de bölgelere göre farklılık ve benzerliklerin incelenmesidir. Yöntem: Çalışmaya, Temmuz 2017- Ekim 2018 tarihleri arasında ÇH tanısıyla izlenen ve genetik çalışması uygulanan 104 çocuk alındı. Google Scholarda Türkiye’de ÇH ve HLA genotiplendirme ile yapılan çalışmalar tarandı (n=11 çalışma) ve bölgelere ayrıldı. Bulgular: Çalışmaya alınan 104 hastanın 67’si kız (%64,4) ve ortalama tanı yaşı 7,9±2,38 yıl(10ay-17,2yıl) idi. Hastalarımızın HLA grupları %59,6 DQ2, %26,9 DQ8 ve %13,4 DQ2+DQ8 saptandı. Literatürdeki çalışmalar bölgeler göre değerlendirildiğinde bizim de içinde bulunduğumuz Karadeniz bölgesinde HLADQ2 %63,7 ve HLADQ8 %21,1 sıklıkla görülürken, bölgemize benzer oranlarda genotip sıklığı Akdeniz ve Doğu Anadolu bölgelerinde görülmektedir. İç Anadolu HLADQ2 %87,4 ve Marmara bölgesinde %83,6 ile daha yüksek frekansta görülmektedir. Çalışmamızda, DQA1*05 %65,4 ve DQB1*02 %12,5 oranında bulundu. Türkiye’deki diğer çalışmalarda (Marmara, Karadeniz, İç, Doğu ve Güneydoğu Anadolu Bölgeleri) görülme sıklığı DQA1*05%69,8 ve DQB1*02 %27,7 idi. Çalışmamızda HLA DQB1*02 homozigot olan hastalarda (%12,5) boy kısalığı, ishal, demir eksikliği anemisi, Marsh3 evre ve akrabalarında ÇH daha yüksekti. Sonuç: Çölyak hastalığında HLA-DQ analizi bölgesel sıklığın belirlenmesi genetik analiz maliyetini azaltmak ve bölgesel dağılıma göre özellikle semptomsuz tarama hastalarında genotiplenme yapılması erken tanı kolaylığı sağlayabilir.


  • Open Access

    Endoscopic Ultrasonography in Pediatric Patients with Pancreatobiliary Disease: Single-Center Trial

    by Fatma Demirbaş, Mustafa Kaymazlı, Gönül Çaltepe, Hasan Abbasguliyev, Ayhan Gazi Kalaycı, Ahmet Bektaş

    Demirbaş F, et al. Pediatr Gastroenterol Hepatol Nutr. 2021 Mar;24(2):164-172. https://doi.org/10.5223/pghn.2021.24.2.164


  • Pre- and Postgastrostomy Evaluation of Gastroesophageal Reflux in Children Using 24-Hour pH Monitoring

    by Fatma Demirbaş, Berat Dilek Demirel, Gönül Çaltepe, Hasan Abbasguliyev, Rıza Ferit Bernay, Ayhan Gazi Kalayci

    Background: The aim of this study was to evaluate 24-hour pH monitoring results before and after gastrostomy in neurological impaired (NI) children who underwent gastrostomy or Nissen fundoplication (NF) concurrently with gastrostomy. Materials and Methods: Between March and December 2018, NI patients who had previously received pre- and postgastrostomy (Group 1) or gastrostomy + NF (Group 2) underwent pH monitoring pre- and postoperatively. Results: Twenty patients [12 males (60%) and the median age of 5.6 (14 months–14.7 years) years] with NI were followed up during the study period. When pre- and postgastrostomy weight and BMI z-scores were compared, the results were significantly higher in both groups after procedure (P = .043, P = .040, respectively). The clinical results of the patients after the operation showed improvement in both groups. The pH index of Group 1 (n = 11) was 2.32 (0–3.8) before gastrostomy and 3.18 (2.1–6.9) after gastrostomy (P = .061) and in Group 2 (n = 9) it was 5.85 (4.9–15.8) and 0.61 (0.3–1.3), before and after procedure (P < .001). There was a statistically significant difference in reflux index of each group. This difference was not statistically significant between the groups (P = .072). When the total bolus exposure index was compared, it was 4.01 (2.1–5.2) before gastrostomy and 5.67 (4.6–6.3) after gastrostomy in Group 1 (P = .041). In group 2, that index was found to be 9.8 (8.3–10.2) before and 1.28 (0.5–1.4) after (P < .001). There was a statistically significant difference in index after gastrostomy in Groups 1 and 2 (P = .023). Conclusions: Gastrostomy feeding is an effective and safe option to achieve enteral feeding in NI children. NF concurrent with gastrostomy should be decided according to the individual patient. Clinical trials protocol registration ID number was PRS NCT 0445112.


  • Association of obesity and non-alcoholic fatty liver disease with the fecal calprotectin level in children

    by Fatma Demirbaş, Gönül Çaltepe, Atakan Comba, Hasan Abbasguliyev, Neval Yurttan Uyar, Ayhan Gazi Kalaycı


  • Diagnostic Challenges of Wilson Disease in Early Childhood

    by Fatma Demirbaş, Ayça Efendioğlu Ağayev, Gönül Çaltepe, Ayhan Gazi Kalaycı


  • A Rare Lesion in Childhood: Gallbladder Tubular Adenoma

    by Fatma Demirbaş, Gönül Çaltepe, Berat Dilek Demirel, Meltem Ceyhan Bilgici, Bilge Can Meydan

  • Fecal calprotectin in children with familial Mediterranean fever in the attack‐free period

    by Fatma Demirbaş, Gönül Çaltepe, Atakan Comba, Hasan Abbasguliyev, Neval Yurttan Uyar, Ayhan Gazi Kalaycı

    Background Familial Mediterranean Fever (FMF) is an autosomal recessive disease characterized by reccurent episodes of fever and serosal inflammation. The aim of this study was to evaluate fecal calprotectin (FC) levels of children with FMF during the non‐attack period. Methods A retrospective evaluation was made of the data of a total 66 patients diagnosed with FMF in an attack‐free period and without amyloidosis/IBD. The FC levels of the patients were compared with the FC levels of patients with IBD and healthy control subjects. Results The FMF patients comprised of 37 (56.1%) males with a mean age of 10.1 ± 3.9 years (range, 5‐17.9 years). The FC levels were determined as 192.5 (19.5‐800) μg/g in the FMF group, 597.9 (180‐800) μg/g in the IBD group, and 43.8 (19.5‐144) μg /g in the control group. The FC level of the children with FMF was higher than that of the control group (P < 0.001), and the FC level of the IBD patients was found to be higher than both of the FMF and the control groups (P = 0.020, P < 0.001, respectively). Conclusions The results of the study showed that the FC levels were higher in FMF patients compared to healthy children even in the absence of IBD/amyloidosis. Even though colonoscopy is the gold standard in determining intestinal inflammation in FMF patients, a non‐invasive and inexpensive method FC can be used for screening. This study indicated the presence of subclinical intestinal inflammation quantitatively in children with FMF.